Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: The OmegAD study

Journal of Internal Medicine

Volumn 275, Issue 4, 2014, Pages 428-436

  Freund Levi, Y ^a   Vedin, I ^a   Cederholm, T ^b   Basun, H ^b   Faxen Irving G ^a   Eriksdotter, M ^a   Hjorth, E ^a   Schultzberg, M ^a   Vessby, B ^b   Wahlund, L O ^a   Salem, N ^c   Palmblad, J ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

Alzheimer's disease; Cerebrospinal fluid; Docosahexaenoic acid; Eicosapentaenoic acid; Omega 3 fatty acids

Indexed keywords

ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; ESSENTIAL FATTY ACID; ICOSAPENTAENOIC ACID; INTERLEUKIN 1 RECEPTOR TYPE II; LINOLENIC ACID; MYRISTIC ACID; OLEIC ACID; OMEGA 3 FATTY ACID; PALMITIC ACID; PLACEBO; STEARIC ACID;

ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; DIET SUPPLEMENTATION; DRUG PENETRATION; FATTY ACID BLOOD LEVEL; HUMAN; PRIORITY JOURNAL;

ALZHEIMER'S DISEASE; CEREBROSPINAL FLUID; DOCOSAHEXAENOIC ACID; EICOSAPENTAENOIC ACID; OMEGA-3 FATTY ACIDS;

ADMINISTRATION, ORAL; ADULT; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BLOOD-BRAIN BARRIER; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; FOLLOW-UP STUDIES; HUMANS; PHOSPHORYLATION; TAU PROTEINS;

EID: 84897024194     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12166     Document Type: Article

References (39)

1. Pawlosky RJ, Denkins Y, Ward G, Salem N Jr. Retinal and brain accretion of long-chain polyunsaturated fatty acids in developing felines: the effects of corn oil-based maternal diets. Am J Clin Nutr 1997; 65: 465-72.
2. Hashimoto M, Tanabe Y, Fujii Y, Kikuta T, Shibata H, Shido O. Chronic administration of docosahexaenoic acid ameliorates the impairment of spatial cognition learning ability in amyloid beta-infused rats. J Nutr 2005; 135: 549-55.
3. Lin DS, Connor WE, Anderson GJ, Neuringer M. Effects of dietary n-3 fatty acids on the phospholipid molecular species of monkey brain. J Neurochem 1990; 55: 1200-7.
4. Anderson GJ, Neuringer M, Lin DS, Connor WE. Can prenatal N-3 fatty acid deficiency be completely reversed after birth? Effects on retinal and brain biochemistry and visual function in rhesus monkeys. Pediatr Res 2005; 58: 865-72.
5. Söderberg M, Edlund C, Kristensson K, Dallner G. Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids 1991; 26: 421-5.
6. Martín V, Fabelo N, Santpere G et al. Lipid alterations in lipid rafts from Alzheimer's disease human brain cortex. J Alzheimers Dis 2010; 19: 489-502.
7. Tully AM, Roche HM, Doyle R. Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case-control study. Br J Nutr 2003; 89: 483-9.
8. McNamara RK. DHA deficiency and prefrontal cortex neuropathology in recurrent affective disorders. J Nutr 2010; 140: 864-8.
9. Cederholm T, Palmblad J. Are omega-3 fatty acids options for prevention and treatment of cognitive decline and dementia? Curr Opin Clin Nutr Metab Care 2010; 13: 150-5.
10. Schaefer EJ, Bongard V, Beiser AS et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol 2006; 63: 1545-50.
11. Freund Levi Y, Eriksdotter-Jönhagen M, Cederholm T et al. Omega-3 fatty acid supplementation delays the cognitive decline in patients with very mild Alzheimer's disease - a 1-year randomized placebo-controlled study of 174 patients. Arch Neurol 2006; 63: 1402-8.
12. Yurko-Mauro K, McCarthy D, Rom D et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement 2010; 6: 456-64.
13. Sarris J, Mischoulon D, Schweitzer J. Omega-3 for bipolar disorder: metaanalyses of use in mania and bipolar depression. J Clin Psychiatry 2012; 73: 81-6.
14. Beydoun MA, Kaufman JS, Satia JA, Rosamond W, Folsom AR. Plasma n-3 fatty acids and the risk of cognitive decline in older adults: the Atherosclerosis Risk in Communities Study. Am J Clin Nutr 2007; 85: 1103-11.
15. Heude B, Ducimetière P, Berr C; EVA Study. Cognitive decline and fatty acid composition of erythrocyte membranes. The EVA Study. Am J Clin Nutr 2003; 77: 803-8.
16. Quinn JF, Raman R, Thomas RG. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease. A randomized trial. JAMA 2010; 304: 1903-11.
17. Freund Levi Y, Hjort E, Lindberg C et al. Effects of omega-3 fatty acids on inflammatory markers in CSF and plasma in Alzheimer's disease. The OmegAD study. Dement Geriatr Cogn Disord 2009; 27: 481-90.
18. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37: 911-7.
19. Morrison WR, Smith LM. Preparation of fatty acid methyl esters and dimethylacetals from lipids with boron-fluoride methanol. J Lipid Res 1964; 5: 600-8.
20. Pilitsis JG, Diaz FG, Wellwood JM et al. Quantification of free fatty acids in human cerebrospinal fluid. Neurochem Res 2001; 26: 1265-70.
21. Rapoport SI. Brain arachidonic and docosahexaenoic acid cascades are selectively altered by drugs, diet and disease. Prostaglandins Leukot Essent Fatty Acids 2008; 79: 153-6.
22. Perez SE, Berg BM, Moore KA et al. DHA diet reduces AD pathology in young APPswe/PS1 Delta E9 transgenic mice: possible gender effects. J Neurosci Res 2010; 88: 1026-40.
23. Hooijmans CR, Van der Zee CE, Dederen PJ et al. DHA and cholesterol containing diets influence Alzheimer-like pathology, cognition and cerebral vasculature in APPswe/PS1dE9 mice. Neurobiol Dis 2009; 33: 482-98.
24. Green KN, Martinez-Coria H, Khashwji H et al. Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. J Neurosci 2007; 27: 4385-95.
25. Calon F, Lim GP, Yang F et al. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 2004; 43: 633-45.
26. Oksman M, Iivonen H, Hogyes E et al. Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol Dis 2006; 23: 563-72.
27. Hashimoto M, Hossain S, Agdul H, Shido O. Docosahexaenoic acid-induced amelioration on impairment of memory learning in amyloid beta-infused rats relates to the decreases of amyloid beta and cholesterol levels in detergent-insoluble membrane fractions. Biochim Biophys Acta 2005; 1738: 91-8.
28. Lim GP, Calon F, Morihara T et al. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci 2005; 25: 3032-40.
29. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010; 6: 131-44.
30. Scheltens P, Kamphuis PJ, Verhey FR et al. Efficacy of a medical food in mild Alzheimer's disease: a randomized, controlled trial. Alzheimers Dement 2010; 6: 1-10.
31. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008; 8: 349-61.
32. Ouellet M, Emond V, Chen CT et al. Diffusion of docosahexaenoic and eicosapentaenoic acids through the blood-brain barrier: an in situ cerebral perfusion study. Neurochem Int 2009; 55: 476-82.
33. Umhau JC, Zhou W, Carson RE et al. Imaging incorporation of circulating docosahexaenoic acid into the human brain using positron emission tomography. J Lipid Res 2009; 50: 1259-68.
34. Oreskovic D, Klarica M. The formation of cerebrospinal fluid: nearly a hundred years of interpretations and misinterpretations. Brain Res Rev 2010; 64: 241-62.
35. Engelhardt B, Sorokin L. The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction. Semin Immunopathol 2009; 31: 497-511.
36. Chen CT, Green JT, Orr SK, Bazinet RP. Regulation of brain polyunsaturated fatty acid uptake and turnover. Prostaglandins Leukot Essent Fatty Acids 2008; 79: 85-91.
37. Chen CT, Liu Z, Bazinet RP. Rapid de-esterification and loss of eicosapentaenoic acid from rat brain phospholipids: an intracerebroventricular study. J Neurochem 2011; 116: 363-73.
38. Chen CT, Liu Z, Ouellet M, Calon F, Bazinet RP. Rapid beta-oxidation of eicosapentaenoic acid in mouse brain: an in situ study. Prostaglandins Leukot Essent Fatty Acids 2009; 80: 157-63.
39. Mazereeuw G, Lanctôt KL, Chau SA, Swardfager W, Herrmann N. Effects of omega-3 fatty acids on cognitive performance: a meta-analysis. Neurobiol Ageing 2012; 33: 1482.e17-29.